Patients’ baseline characteristics.
| Variable | Overall |
|---|---|
| Patients | 23 |
| Age (years), mean (SD) | 76 (8.5) |
| Sex (%) | |
| 2 (9) |
| 21 (91) |
| Height (cm), mean (SD) | 165.3 (8.9) |
| Body weight (kg), mean (SD) | 62.5 (12) |
| Body mass index (kg/m2), mean (SD) | 23.2 (3.7) |
| T category (%) | |
| 7 (30) |
| 12 (52) |
| 4 (17) |
| Tumor grade (%) | |
| 11 (48) |
| 12 (52) |
| Number of tumors (%) | |
| 4 (17) |
| 13 (57) |
| 2 (9) |
| 4 (17) |
| Longest diameter (cm), mean (SD) | 3.0 (1.4) |
| CIS (%) | 5 (22) |
| Maintenance of BCG (%) | 3 (13) |
| Overall follow-up period (month), median (IQR) | 89 [57, 108.0] |
| Overall survival (%) | 3 (13) |
| Overall survival (month), median (IQR) | 81.8 [52.2, 99.1] |
| Recurrence (%) | 10 (44) |
| Recurrence-free survival (month), median (IQR) | 58.1 [17.9, 85.1] |
| Progression (%) | 8 (35) |
| Progression-free survival (months), median (IQR) | 60.5 [46.4, 86.6] |
Demographic and clinicopathological characteristics of the 23 patients with non-muscle invasive bladder cancer (NMIBC) included in the analysis. Data are presented as mean ± standard deviation (SD) for continuous variables and number (percentage) for categorical variables unless otherwise indicated. Survival times are reported as median [interquartile range (IQR)]. BCG: Bacillus Calmette–Guérin; HG: high grade; LG: low grade.
The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002365_sup_1.pdf. The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002365_sup_2.xlsx.
We thank the patients who participated in this study. We also thank Sayuri Onishi and Mariko Yoshimura (Department of Urology, Nara Medical University, Nara, Japan) for their technical assistance. The authors are responsible for obtaining permission from the acknowledged individuals and institutions.
YO: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing—original draft, Writing—review & editing. MM: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Writing—review & editing, Funding acquisition. NN, TS, TO, KI, YN: Data curation, Writing—review & editing. NT, KF: Supervision, Data curation, Writing—review & editing. All authors read and approved the submitted version.
Yuki Oda and Makito Miyake, who are the Guest Editors of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or review process of this manuscript. The other authors declare no conflicts of interest.
The study was approved by the Nara Medical University Ethics Committee (No. 3698).
Written informed consent to participate in the study was obtained from all participants.
Written informed consent for publication of de-identified data was obtained from all participants.
Raw 16S rRNA gene sequencing reads have been deposited in the NCBI Sequence Read Archive (SRA) under BioProject PRJNA1413953. Other datasets generated for this study are available from the corresponding author on reasonable request.
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number 23K08720 to Makito Miyake). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.